SCNINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Scinai Immunotherapeutics Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026
$0.75−0.00 (-0.32%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Scinai Immunotherapeutics statistics
Financials through Dec 31, 2025, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Scinai Immunotherapeutics | Industry median |
|---|---|---|
| Market Cap | $2.60M | $164.85M |
| Enterprise Value | $940.17K | $87.06M |
| PS Ratio | 1.98 | 3.60 |
| PB Ratio | 0.32 | 2.03 |
| P/TBV Ratio | 0.32 | 2.31 |
Enterprise value
| Measure | Scinai Immunotherapeutics | Industry median |
|---|---|---|
| EV / Sales | 0.72 | 2.43 |
Income (trailing twelve months)
| Measure | Scinai Immunotherapeutics | Industry median |
|---|---|---|
| Revenue | $1.31M | $57.94M |
| Gross Profit | -$2.65M | $90.47M |
| Operating Income | -$7.54M | -$21.44M |
| Net Income | -$8.31M | -$22.46M |
| EBITDA | -$6.12M | -$16.91M |
Margins
| Measure | Scinai Immunotherapeutics | Industry median |
|---|---|---|
| Gross Margin | -202.3% | 52.3% |
| Operating Margin | -575.3% | -44.5% |
| Profit Margin | -633.6% | -39.2% |
| EBITDA Margin | -466.9% | -31.3% |
| FCF Margin | -461.9% | -8.85% |
Returns
| Measure | Scinai Immunotherapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -91.9% | -53.1% |
| Return on Assets (ROA) | -66.3% | -41.0% |
| Return on Invested Capital (ROIC) | -82.4% | -32.0% |
| Return on Capital Employed (ROCE) | -75.1% | -37.8% |
Growth
| Measure | Scinai Immunotherapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 99.2% | 6.01% |
| Net Income Growth (YoY) | -273.2% | -37.7% |
Balance sheet
| Measure | Scinai Immunotherapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $1.66M | $62.42M |
| Net Cash (Debt) | $1.66M | $15.68M |
| Net Cash Per Share | $0.00 | $0.66 |
| Equity (Book Value) | $8.10M | $48.79M |
| Book Value Per Share | $0.00 | $1.36 |
| Tangible Book Value | $8.10M | $23.06M |
| Working Capital | $469.00K | $75.77M |
Financial position
| Measure | Scinai Immunotherapeutics | Industry median |
|---|---|---|
| Current Ratio | 1.30 | 3.30 |
| Quick Ratio | 1.09 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Scinai Immunotherapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$6.03M | -$12.35M |
| Capital Expenditures | -$24.00K | -$1.06M |
| Free Cash Flow | -$6.06M | -$20.28M |
| FCF Per Share | -$0.00 | -$0.42 |
Efficiency
| Measure | Scinai Immunotherapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.10 | 0.38 |
| Revenue Per Employee | $29.13K | $398.96K |
| Profits Per Employee | -$184.60K | -$703.34K |
| Employee Count | 45 | 74 |
Dividends and yields
| Measure | Scinai Immunotherapeutics | Industry median |
|---|---|---|
| Earnings Yield | -319.4% | -22.7% |
| FCF Yield | -232.8% | -9.07% |
Shares
| Measure | Scinai Immunotherapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 13,872,900,000 | 58,179,650 |
| Shares Change (YoY) | 189.6% | 11.1% |
| Float | 12,847,400,000 | 49,173,100 |
| Shares Held by Insiders | 7.39% | 11.6% |
Scores
| Measure | Scinai Immunotherapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -16.69 | -0.24 |
| Piotroski F-Score | 3 | 4 |
| Beneish M-Score | -3.20 | -2.62 |
Calculated by StockData from Scinai Immunotherapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.